Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25430953 | 0.77 | CHEK1 (0.32) | — | |
| SCHEMBL31595062 | 0.75 | WNT1 (0.33) | GAA | |
| SCHEMBL26054214 | 0.75 | — | — | |
| SCHEMBL31595123 | 0.74 | — | — | |
| SCHEMBL26055132 | 0.74 | — | — | |
| SCHEMBL26055136 | 0.74 | TNKS2 (0.33) | — | |
| SCHEMBL26054215 | 0.74 | LPAR1 (0.34) | — | |
| SCHEMBL25433974 | 0.73 | KCNQ3 (0.34) | — | |
| SCHEMBL31582096 | 0.73 | GAA (0.34) | GAA | |
| SCHEMBL31594944 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230152-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250171429-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4482489-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118695860-A | Pyrazolyl compounds as KV7 channel activators | 拜奥海芬治疗学有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023164536-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164536-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230152-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNT1 | GAA 1794/4885ADORA2A 2978/4885 |
| US-20250171429-A1 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNT1 | GAA 1794/4885ADORA2A 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.